source
- Epicrispr raises $90 million Series C after promising early data on epigenetic FSHD therapyEpicrispr Biotechnologies announced a $90 million Series C financing round to advance its research program. The company shared early data suggesting that an epigenetic approach could address facio…
- Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assetsYing Huang spent the past seven years building one of the leading cancer cell‑therapy companies before stepping down as CEO of Legend Biotech. Weeks after announcing his departure, Huang has taken…